An optimization framework to guide the choice of thresholds for risk-based cancer screening.


Journal

NPJ digital medicine
ISSN: 2398-6352
Titre abrégé: NPJ Digit Med
Pays: England
ID NLM: 101731738

Informations de publication

Date de publication:
28 Nov 2023
Historique:
received: 14 07 2023
accepted: 15 11 2023
medline: 29 11 2023
pubmed: 29 11 2023
entrez: 28 11 2023
Statut: epublish

Résumé

It is uncommon for risk groups defined by statistical or artificial intelligence (AI) models to be chosen by jointly considering model performance and potential interventions available. We develop a framework to rapidly guide choice of risk groups in this manner, and apply it to guide breast cancer screening intervals using an AI model. Linear programming is used to define risk groups that minimize expected advanced cancer incidence subject to resource constraints. In the application risk stratification performance is estimated from a case-control study (2044 cases, 1:1 matching), and other parameters are taken from screening trials and the screening programme in England. Under the model, re-screening in 1 year for the highest 4% AI model risk, in 3 years for the middle 64%, and in 4 years for 32% of the population at lowest risk, was expected to reduce the number of advanced cancers diagnosed by approximately 18 advanced cancers per 1000 diagnosed with triennial screening, for the same average number of screens in the population as triennial screening for all. Sensitivity analyses found the choice of thresholds was robust to model parameters, but the estimated reduction in advanced cancers was not precise and requires further evaluation. Our framework helps define thresholds with the greatest chance of success for reducing the population health burden of cancer when used in risk-adapted screening, which should be further evaluated such as in health-economic modelling based on computer simulation models, and real-world evaluations.

Identifiants

pubmed: 38017184
doi: 10.1038/s41746-023-00967-9
pii: 10.1038/s41746-023-00967-9
pmc: PMC10684532
doi:

Types de publication

Journal Article

Langues

eng

Pagination

223

Subventions

Organisme : Breast Cancer Now
ID : 2019DecPR1395
Pays : United Kingdom
Organisme : Breast Cancer Now
ID : 2019DecPR1395
Pays : United Kingdom

Informations de copyright

© 2023. The Author(s).

Références

Br J Cancer. 2022 May;126(9):1355-1361
pubmed: 35110696
Best Pract Res Clin Obstet Gynaecol. 2020 May;65:3-17
pubmed: 31848103
Rev Epidemiol Sante Publique. 1998 Nov;46(5):420-6
pubmed: 9864771
Breast Cancer Res Treat. 2008 Feb;107(3):309-30
pubmed: 17377838
Stat Sci. 2020 Mar 3;35(1):14-30
pubmed: 32226220
BMC Cancer. 2021 May 29;21(1):637
pubmed: 34051753
Br J Cancer. 2018 Jun;118(12):1648-1657
pubmed: 29736008
J Clin Oncol. 2009 Dec 10;27(35):5919-23
pubmed: 19884547
Int J Cancer. 2021 Apr 12;:
pubmed: 33844853
Sci Transl Med. 2021 Jan 27;13(578):
pubmed: 33504648
Radiology. 2023 Jun;307(5):e222733
pubmed: 37278627
BMJ. 2007 Aug 25;335(7616):358-9
pubmed: 17717337
J Clin Oncol. 2022 Jun 1;40(16):1732-1740
pubmed: 34767469
J Pers Med. 2021 Sep 15;11(9):
pubmed: 34575693
Radiol Artif Intell. 2020 Nov 25;3(1):e200103
pubmed: 33937853
Radiology. 2023 Jun;307(5):e222679
pubmed: 37310244
Radiol Clin North Am. 2000 Jul;38(4):625-51
pubmed: 10943268
JAMA Oncol. 2018 Nov 1;4(11):1504-1510
pubmed: 29978189
J Clin Oncol. 2023 Jun 10;41(17):3172-3183
pubmed: 37104728
Nat Med. 2022 Jan;28(1):136-143
pubmed: 35027757
J Natl Cancer Inst. 2017 Jan 27;109(5):
pubmed: 28130475
Cancer. 1995 May 15;75(10):2507-17
pubmed: 7736395
Epidemiol Prev. 2013 Jul-Oct;37(4-5):317-27
pubmed: 24293498
J Natl Med Assoc. 2020 Dec;112(6):613-618
pubmed: 32654804
Value Health. 2017 Sep;20(8):1100-1109
pubmed: 28964442

Auteurs

Adam R Brentnall (AR)

Wolfson Institute of Population Health, Queen Mary University of London, London, UK. a.brentnall@qmul.ac.uk.

Emma C Atakpa (EC)

Wolfson Institute of Population Health, Queen Mary University of London, London, UK.

Harry Hill (H)

Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield, UK.

Ruggiero Santeramo (R)

Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
Warwick Manufacturing Group, University of Warwick, Coventry, UK.

Celeste Damiani (C)

Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
Data Science & Computation Facility, Fondazione Istituto Italiano di Tecnologia, Genoa, Italy.

Jack Cuzick (J)

Wolfson Institute of Population Health, Queen Mary University of London, London, UK.

Giovanni Montana (G)

Warwick Manufacturing Group, University of Warwick, Coventry, UK.

Stephen W Duffy (SW)

Wolfson Institute of Population Health, Queen Mary University of London, London, UK.

Classifications MeSH